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Abstract
Objectives: To determine the extent that zoledronate (ZOL) dose and duration is as-
sociated with bisphosphonate-related osteonecrosis of the jaw (BRONJ) prevalence 
in rice rats with generalized periodontitis (PD), characterize structural and tissue-
level features of BRONJ-like lesions in this model, and examine the specific anti-re-
sorptive role of ZOL in BRONJ.
Materials and Methods: Rice rats (n = 228) consumed high sucrose-casein diet to 
enhance generalized PD. Groups of rats received 0, 8, 20, 50 or 125 µg/kg IV 
ZOL/4 weeks encompassing osteoporosis and oncology ZOL doses. Rats from each 
dose group (n = 9–16) were necropsied after 12, 18, 24 and 30 weeks of treatment. 
BRONJ-like lesion prevalence and tissue-level features were assessed grossly, histo-
pathologically and by MicroCT. ZOL bone turnover effects were assessed by femoral 
peripheral quantitative computed tomography, serum bone turnover marker ELISAs 
and osteoclast immunolabelling.
Results: Prevalence of BRONJ-like lesions was significantly associated with (a) ZOL 
treatment duration, but plateaued at the lowest oncologic dose, and (b) there was a 
similar dose-related plateau in the systemic anti-resorptive effect of ZOL. ZOL and 
BRONJ-like lesions also altered the structural and tissue-level features of the jaw.
Conclusion: The relationship between BRONJ-like lesion prevalence and ZOL dose 
and duration varies depending on the co- or pre-existing oral risk factor. At clinically 
relevant doses of ZOL, BRONJ-like lesions are associated with anti-resorptive 
activity.
K E Y W O R D S
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1  | INTRODUC TION
Medication-related osteonecrosis of the jaw (MRONJ) is a potentially 
severe adverse event characterized by persistent exposure of ne-
crotic bone in the jaw (Ruggiero et al., 2014) in patients treated with 
potent anti-resorptives (pARs) [e.g., nitrogen-containing bisphos-
phonates, N-BPs (Marx, 2003; Ruggiero et al., 2014), and receptor 
activator of NFκB ligand antibodies (Stopeck et al., 2010; Van den 
Wyngaert, Wouters, Huizing, & Vermorken, 2011)]. More recently, 
MRONJ has been observed in patients with cancer taking anti-angio-
genic medication (e.g., vascular endothelial growth factor antibod-
ies) (Carlson & Schlott, 2014; Eleutherakis-Papaiakovou & Bamias, 
2017; Fusco, Santini, Armento, Tonini, & Campisi, 2016; Khan et al., 
2017; Ramirez, Lopez-Pintor, Casanas, Arriba, & Hernandez, 2015; 
Voss, Poxleitner, Schmelzeisen, Stricker, & Semper-Hogg, 2017). In 
ONJ cases in which the only systemically administered medication is 
an N-BP, the term bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) may also be used.
Systemic administration of these medications is specified in 
the clinical definition of MRONJ as a requirement for a formal di-
agnosis (Ruggiero et al., 2014). However, local factors in the oral 
cavity, despite being absent from the formal definition of MRONJ, 
also increase risk and play a crucial role in the disease process 
(Aghaloo, Hazboun, & Tetradis, 2015; Aljohani et al., 2017; Carlson 
& Schlott, 2014; Eleutherakis-Papaiakovou & Bamias, 2017; Filleul, 
Crompot, & Saussez, 2010; Hamadeh, Ngwa, & Gong, 2015; Khan 
et al., 2017; Marx, 2003; Otto et al., 2012; Voss et al., 2017; 
Yoneda et al., 2017).
Discrete oral procedures involving the dentoalveolar bone 
(e.g., tooth extraction) are considered the most common local 
oral factor associated with MRONJ and are estimated to occur 
in 52%–86% of MRONJ cases (Aghaloo et al., 2015; Aljohani et 
al., 2017; Carlson & Schlott, 2014; Eleutherakis-Papaiakovou & 
Bamias, 2017; Filleul et al., 2010; Hamadeh et al., 2015; Khan et 
al., 2017; Marx, 2003; Otto et al., 2012; Ruggiero et al., 2014; Voss 
et al., 2017; Yoneda et al., 2017). Delaying the start of risk factor 
medications until surgical sites have healed, and ensuring appro-
priate perioperative management, including antibiotic coverage, 
are often effective means to prevent MRONJ associated with den-
toalveolar surgery (Dimopoulos et al., 2009; Hoefert & Eufinger, 
2011; Montefusco et al., 2008; Ripamonti et al., 2009; Vandone 
et al., 2012). However, periodontitis (PD) and periapical infection 
(Aghaloo et al., ; Aguirre, Akhter, Kimmel, Pingel, Williams et al., 
2012; Li et al., 2016; Song et al., 2016) have also been identified as 
important risk factors for BRONJ/MRONJ in patients without re-
cent dentoalveolar surgery (Carlson & Schlott, 2014; Eleutherakis-
Papaiakovou & Bamias, 2017; Khan et al., 2017; Marx, 2003; Voss 
et al., 2017). While oral diseases involving the periodontal tissues 
appear to contribute to MRONJ directly, they may also contribute 
to cases related to dentoalveolar surgery, since teeth that require 
extraction often have some degree of acute or chronic infection 
(e.g., infection from caries, periodontal disease). Cases in which 
MRONJ arises without a recent dentoalveolar surgery may be 
more difficult to anticipate and treat, especially if these conditions 
are not fully resolved before beginning pAR treatment, or if they 
arise after pAR treatment has started. Therefore, studies that in-
vestigate the role of specific oral inflammatory diseases as local 
oral risk factors for MRONJ are important to develop a compre-
hensive understanding of the pathophysiology of the disease, and 
contribute evidence that might be used to develop preventative or 
therapeutic strategies.
Rice rats (Oryzomys palustris) develop two distinctive types of PD 
that require no surgical or local mechanical intervention: (a) a gener‐
alized form, which affects both maxillae and mandibles, and is accel-
erated by a high sucrose-casein diet (HSC) (Aguirre, Akhter, Kimmel, 
Pingel, Xia et al., 2012; Aguirre et al., 2016; Gotcher & Jee, 1981; 
Gupta & Shaw, ); and (b) a localized form (food impaction localized PD, 
FILP), which overwhelmingly affects the maxillary interdental space 
between molar (M) 2 and M3 and is found in rice rats fed standard 
rodent chow (STD) (Messer et al., 2017). Importantly, rice rats fed 
HSC diet do not develop FILP lesions. Therefore, two different PD 
models can be generated in rice rats by dietary modification alone. 
The pelleted HSC diet that accelerates generalized PD is based on 
the powdered Harvard high sucrose 700 and the ration 100 diets 
used in previous studies to accelerate the onset of PD in rice rats 
(Auskaps, Gupta, & Shaw, 1957; Gotcher & Jee, 1981; Gupta & Shaw, 
; Ryder, 1980). The reason the pelleted HSC diet does not produce 
FILP (Aguirre, Akhter, Kimmel, Pingel, Williams et al., 2012; Aguirre, 
Akhter, Kimmel, Pingel, Xia et al., 2012) is possibly due to the low 
content (3%) of insoluble fibre provided as powdered cellulose, 
which is in contrast to STD rodent chow (irradiated diet no. 7912, 
Teklad LM-485 Rodent Diet; Envigo, Tampa, FL), which contains 
13.7% neutral detergent fibre (NDF) and 4.6% of crude fibre. These 
fibrous components of the STD chow diet appear to contribute to 
the initiation and persistence of FILP lesions.
The defining feature of the FILP model is direct injury to soft 
tissue in the maxillary interdental M2-M3 space by persistent 
presence of impacted plant fibre and cellular debris. Food im-
paction around teeth, dental implants, or embrasures in humans 
may also result in peri-implantitis or peri-coronitis (Du, Gao, Qi, 
Liu, & Lin, 2010), and is an important risk factor for localized PD 
in humans (Matthews & Tabesh, 2004; Nunn, 2003). Conversely, 
clinical and histopathologic examination of generalized PD in the 
rice rat shows marked accumulation of microbial plaque on molar 
surfaces and inflammation of periodontal tissues. This type ap-
pears to resemble human PD, in which biofilms are an import-
ant mediator and contributing factor to the pathophysiology 
of the disease (Genco & Borgnakke, 2013; Offenbacher, 1996; 
Page, Offenbacher, Schroeder, Seymour, & Kornman, 1997; Salvi, 
Lawrence, Offenbacher, & Beck, 1997).
Rice rats with either type of PD, and without dentoalveolar sur-
gery, develop BRONJ-like lesions when simultaneously exposed 
to clinically relevant doses of the systemic pAR, zoledronate (ZOL) 
(Aguirre, Akhter, Kimmel, Pingel, Williams et al., 2012; Messer et al., 
2018). Importantly, the anatomical distribution of BRONJ-like le-
sions appears to be associated with the anatomical location of the 
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PD in individual rats. Specifically, rice rats fed STD diet and injected 
with ZOL developed BRONJ-like lesions primarily at the same lo-
cation as the FILP lesions, the M2M3 maxillary interdental space 
(Messer et al., 2018), whereas rats fed HSC diet and injected with 
oncologic ZOL developed BRONJ-like lesions equally in the four jaw 
quadrants (Aguirre, Akhter, Kimmel, Pingel, Williams et al., 2012). 
These findings suggest that rats given clinically relevant doses of 
ZOL are more likely to develop BRONJ-like lesions in quadrants that 
are also directly affected by oral inflammation.
In humans, various local oral risk factors (e.g., oral infections, sur-
gical/trauma events and inflammatory disease), when combined with 
systemic risk factor medications, can result in MRONJ. However, it 
is not clear if different local oral risk factors result in distinctive pat-
terns in the relationship between MRONJ prevalence and dose and 
duration of systemic risk factor medications. The rice rat provides a 
unique opportunity to explore this hypothesis given the distinctive 
types of PD that exist in this species. Previous findings demonstrated 
that BRONJ-like lesions occur in rice rats with localized PD (FILP) in 
a positive dose-dependent manner, but ZOL duration did not have 
a significant effect on the prevalence of BRONJ-like lesions, which 
plateaued between 18 and 30 weeks of treatment (Messer et al., 
2018). Importantly, 50%–75% of vehicle-treated STD diet rats show 
FILP-induced mucosal injury by age 16 weeks. This finding is in di-
rect contrast to the age-related progression of generalized PD which 
does not become moderate to severe in a majority of rats until later, 
at age 22 weeks (Aguirre, Akhter, Kimmel, Pingel, Xia et al., 2012). 
These findings suggest that the effect of ZOL dose and duration on 
BRONJ-like lesion prevalence in rice rats with generalized PD could 
differ from that in rice rats with localized PD. Examining how differ-
ent oral risk factors work alongside systemic medications may pro-
vide important data that improves the current understanding of how 
different periodontal risk factors interact with systemic medications 
to initiate MRONJ.
The primary purposes of this study were to: (a) define the rela-
tionship between ZOL dose and duration and prevalence of BRONJ-
like lesions in rice rats with generalized PD, (b) characterize the 
overall structure and tissue-level features of alveolar bone in ZOL-
treated rice rats with and without BRONJ-like lesions by MicroCT 
and histologic techniques and (c) examine the association between 
the anti-resorptive effect of ZOL at clinically relevant doses and the 
presence of BRONJ-like lesions.
We hypothesize that: (a) increased dose and duration of ZOL will 
increase the prevalence of BRONJ-like lesions in rice rats with gen-
eralized PD in a pattern that is distinctive from previous findings in 
rats with localized PD; (b) ZOL and BRONJ-like lesions will alter the 
structure and tissue-level features of the jaw; and (c) ZOL dose will 
be associated with reduced osteoclast number in the jaw and sup-
pressed systemic bone resorption. Testing the first hypothesis will 
involve using data from a previously reported experiment (Messer et 
al., 2018) conducted simultaneously to this one.
2  | MATERIAL S AND METHODS
2.1 | Animal care
A monogamous continuous-breeding system was used to generate 
the experimental rice rats. All rats were housed (2–5 per cage) in 
static filter top cages (area: 143 in2) with pine shavings and continu-
ous access to food and water. The housing rooms were maintained at 
20–26ºC with humidity of 30%–70% and a 12:12 hr light:dark cycle, 
or 14:10 hr cycle for breeders (Aguirre et al., 2015). Experimental an-
imals ate pelleted, semi-purified HSC diet (TestDiet 5SXA AIN-93G 
w/no Complex Carbohydrates; Smelt Feed and Pet Supply, Tampa, 
FL, USA), which can be fed for up to 30 weeks without inducing sig-
nificant metabolic abnormalities (Aguirre et al., 2016). This diet is 
based on the formula of the powdered Harvard high sucrose 700 
diet and the ration 100 diet previously used to accelerate gener-
alized PD in rice rats (Auskaps et al., 1957; Gotcher & Jee, 1981; 
Gupta & Shaw, ; Ryder, 1980). Breeder rats ate rodent breeder chow 
(Envigo Teklad, irradiated 2919). Body weight (BW) was measured 
bi-weekly. If rats showed BW loss and/or reduced body condi-
tion score (BCS), saline was administered subcutaneously and gel 
diet was offered (Ullman-Cullere & Foltz, 1999). The Animal Care 
Services resource at the University of Florida (UF) is an AAALAC-
accredited programme. The breeding (IACUC#201408452) and ex-
perimental (IACUC#201408453) protocols were approved by the 
UF Institutional Animal Care and Use Committee (IACUC), and all 
experiments were compliant with the ARRIVE guidelines.
F I G U R E  1   Experimental design. Rats 
were weaned at age 4 weeks, placed on 
high sucrose-casein diet and randomized 
into dosing groups. Starting at age 
4 weeks, rats received tail vein injections 
of 0, 8, 20, 50 or 125 µg/kg zoledronate 
(ZOL) q4wks until necropsy. One group 
of rats was necropsied at age 4 weeks 
(n = 12). Groups of rats (n = 9–16) within 
each dose level were necropsied at 12, 18, 
24 or 30 weeks of ZOL treatment
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2.2 | Study design
Two hundred and twenty-eight clinically normal, female weanling 
rice rats (BW ≥ 30 g; BCS ≥ 3.0) were BW-randomized into a base-
line group (n = 12; age, 4 weeks) or one of five dose groups (Figure 1), 
with efforts made to assign littermates into different dose groups. 
A previous study showed that both male and female rice rats given 
oncologic doses of ZOL develop BRONJ (Aguirre, Akhter, Kimmel, 
Pingel, Williams et al., 2012). Only females were used in the current 
study to avoid variation in measurements due to sexual dimorphism 
(Aguirre et al., 2015). All groups were fed pelleted HSC diet and re-
ceived intravenous (IV) injections of 0 (n = 42), 8 (n = 44), 20 (n = 44), 
50 (n = 40), or 125 µg/kg BW of ZOL (n = 46) every four weeks 
(q4wk), starting at 4 weeks of age. After 12, 18, 24 and 30 weeks of 
treatment, duration subgroups (n = 9–16) from each of the five dose 
groups were necropsied (Supporting Information Table S1 and Figure 
S1). The minimum sample size (n = 9) was determined by power cal-
culation (see Statistical Analysis, Section 2.11). Animals were added 
to later time points based on a 10% censor rate to account for rats 
removed from the study before reaching scheduled time points, 
based on attrition rates from previous long-term rice rat studies. 
To compose each duration subgroup, rats with progressive BW loss 
that reached ≥15% were chosen to comply with humane endpoints 
specified in the IACUC protocol. The remaining rats for each duration 
subgroup were selected by BW randomization. No more than 30% of 
each dose/duration subgroup was composed of rats that met the BW 
loss endpoint criteria for euthanasia.
2.3 | ZOL dose
The dosing strategy has been previously described (Messer et al., 
2018). Briefly, we used 8 μg/kg IV q4wk as the rat equivalent of 
the human osteoporosis (OP) dose. The dose gradient in the cur-
rent study includes 0, 8, 20, 50 and 125 µg/kg, which encompasses 
both the OP and a range of oncologic ZOL doses. For each dose con-
centration, ZOL was dissolved in normal sterile saline (pH 7.2). ZOL 
was injected into the tail vein of rats placed in rodent restrainers at 
the rate of 0.4 ml/100 g BW. ZOL was kindly provided by Novartis 
Pharma AG (Basel, Switzerland).
2.4 | Euthanasia and tissue collection
Rats were euthanized by CO2 followed by cardiac puncture to with-
draw about 1.5 ml of whole blood. Cervical dislocation was used 
as a secondary confirmatory method of euthanasia. Maxillae and 
mandibles were excised as before (Messer et al., 2018). High-resolu-
tion (HR) photographs from the medial aspect of each hemi-mandi-
ble (Supporting Information Figure S2a) and ventral aspect of each 
hemi-maxillae (Supporting Information Figure S2b) were taken with 
a digital camera (Canon EOS 6D; Tokyo, Japan) attached to a macro 
lens (Canon EF 100 mm 1:2.8; Tokyo, Japan). Jaw quadrants were 
fixed at 4°C in freshly prepared 4% paraformaldehyde, then trans-
ferred to 70% ethanol after 48 hr.
2.5 | Gross analysis of oral lesions
Jaw quadrant photographs were independently assessed by blinded 
observers (JGM, DBK, JIA). Quadrants were assigned a Gross 
Quadrant Grade (GQG) that reflected the severity of its gross lesions 
(Table 1) (Messer et al., 2018). Photographs of representative maxil-
lae and mandibles representing each GQG are shown in Supporting 
Information Figure S2. When at least one quadrant in a rat had an 
area of exposed bone, the rat was considered positive for a gross 
BRONJ-like lesion. Neither pocket depth nor clinical attachment 
level by probing were evaluated. Photographs that did not receive 
the same GQG from all three independent observers were re-exam-
ined by all three observers together, and a GQG was assigned when 
consensus was reached.
2.6 | Histopathologic assessment of quadrants
2.6.1 | Specimen selection for histopathologic 
BRONJ‐like lesion analysis
Histopathologic confirmation of BRONJ-like cases was undertaken 
in rats that were: (a) diagnosed with gross BRONJ-like lesions; (b) 
not diagnosed with gross BRONJ-like lesions, but had quadrants 
with oral lesions of GQG ≥2; and (c) not diagnosed with gross 
BRONJ-like lesions, but experienced prenecropsy BW loss (see 
Supporting Information Figure S1). Quadrants with GQG ≥ 2 were 
selected because these quadrants displayed gross gingival recession 
TA B L E  1   Criteria for Gross Quadrant Score (GQG)
Score Degree Description
0 None Normal gingival contours
1 Slight Minimal plaque, minimal gingival recession
2 Mild Plaque, recession/ulceration of gingiva 
with limited extension towards lingual 
plate or palatal midline; inflammation/
swelling/redness at margin of lesion
3 Moderate Plaque, recession/ulceration gingival 
extending into lingual mucosa towards 
midline in maxilla or onto lingual mucosa 
in mandible; inflammation/swelling/
redness at margin of lesion; possible 
involvement of buccal mucosa, possible 
tooth migration
4 Severe Profound plaque accumulation, extensive 
gingival recession/ulceration involving all 
three molars and extending into lingual 
mucosa towards the midline and onto the 
buccal mucosa; gingival inflammation/
redness; loss of alveolar bone with 
furcation exposure, tooth migration or 
tooth loss
BRONJ  Lesion of GQG = 3 or 4 with exposure of 
alveolar or palatal bone
Note. See Supporting Information Figure 2 for corresponding 
photographs.
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and ulceration. For rats with BW loss, all quadrants were analysed 
because data from a previous study showed that rice rats with 
BRONJ-like lesions had BW loss compared to rice rats without these 
lesions (Messer et al., 2018). In the current study, 37% (80/218) 
of rats necropsied at weeks 12–30 exhibited BW loss. 92% of rats 
with gross BRONJ-like lesions (22/24) and 73% (22/30) of rats with 
BRONJ-like lesions diagnosed only using histopathology (without 
prior gross diagnosis) had BW loss.
2.6.2 | Specimen selection for PD analysis
Right maxillae and mandibles from all ZOL 0 rats, and right maxillae 
from baseline rats, regardless of GQG, were examined to determine 
periodontal status and assigned a PD Score (Table 2). When right 
quadrants were not available, left quadrants were used.
2.7 | Histological preparation of jaw quadrants
Maxillae and mandibles selected for sectioning were decalcified 
in 5% formic acid under gentle agitation for 4 weeks, with three 
changes per wk. Decalcified jaw quadrants were trimmed, paraf-
fin-embedded, and sectioned at 5 µm thickness in the mesiodistal 
plane from the lingual to buccal aspect of each quadrant (Leica/
Jung 2265 and Accu-Cut SRM 200 Sakura microtomes, Sakura 
Finetek Europe B.V, Zoeterwoude, The Netherlands). Maxillae and 
mandibles were serially sectioned at five or six levels, starting ap-
proximately 1 mm lateral to the midline of the palate or at the lin-
gual plate, respectively. Levels were separated by approximately 
250 µm, allowing thorough examination of tissues at the lingual 
surface (one or two levels), around the molars (three levels), and 
at the buccal surface (one level). Sections were H&E stained and 
cover slipped.
2.7.1 | Histopathologic definition of BRONJ‐like 
lesions and quantification of necrotic bone
Histopathologic BRONJ-like lesions were defined as bone that was 
both exposed and necrotic in at least one level within a quadrant. 
Exposed bone was identified by a lack of overlying gingival epithe-
lium, lamina propria, and periodontal ligament (PDL). Necrotic bone 
was identified using (a) a pattern recognition approach as previously 
described (Franco-Pretto, Pacheco, Moreno, Messa, & Gnecco, 
2014; Hellstein, 2014; Yang et al., 2009; Zheng et al., 2018), and (b) 
by specific criteria used in previous preclinical studies of BRONJ that 
define necrotic bone as bone matrix containing ≥10 adjacent lacunae 
that were empty, or had pyknotic osteocyte nuclei or cellular debris 
(Kuroshima & Yamashita, 2013; Yamashita, Koi, Yang, & McCauley, 
2011). All levels were surveyed independently by two observers 
(JGM and JIA). When diagnoses differed, agreement was reached 
after reviewing slides together. A rat with at least one quadrant that 
met the definition above was considered positive for BRONJ.
To quantify bone necrosis, the number of lacunae that were 
empty or contained pyknotic nuclei was counted. Data collection 
was performed at 200× magnification in sections within a 0.15–0.25 
mm2 region of interest (ROI) that contained exposed bone matrix in a 
BRONJ-like lesion, or an area of bone with periodontal tissue destruc-
tion and inflammation in FILP lesions with GQG ≥ 1. Total bone area 
(B.Ar, mm2), total number of osteocyte lacunae, and number of empty 
osteocyte lacunae were measured. The percentage of empty lacunae, 
and the number of empty lacunae per B.Ar (#/mm2), were calculated.
2.7.2 | Histopathologic characterization of PD
Sections were assessed for PD Score (Table 2) and alveolar bone loss 
as previously described (Aguirre, Akhter, Kimmel, Pingel, Xia et al., 
2012). A quadrant with PD Score ≥1 was considered positive for PD. 
A rat with at least one quadrant with PD Score ≥1 was considered 
positive for PD. The rat PD Score is the highest quadrant PD score 
for that animal. Alveolar bone height (ABH) was assessed in both 
maxillae and mandibles by measuring the distance between the ce-
mentoenamel junction (CEJ) and the crest of the alveolar bone, as 
previously described (Figure 2d) (Aguirre, Akhter, Kimmel, Pingel, 
Williams et al., 2012; Aguirre et al., 2016). Measurements were 
made in one section from the lingual aspect of the M1M2 interden-
tal space. A larger ABH value indicates greater loss of alveolar bone. 
Measurements were made in blinded, randomized order (JGM). ABH 
in baseline rats was only measured in maxillae.
2.7.3 | Osteoclast quantification
To assess the local effect of ZOL, PD, and BRONJ on osteoclasts in the 
jaws, osteoclasts were analysed on the surfaces of maxillary alveolar 
TA B L E  2   PD score (inflammation scoring system)
Score Degree Description
0 Absence None
1 Slight Gingivitis: slight hyperplasia of GE, 
intraepithelial inflammatory cell 
infiltration. Bacterial plaque accumula-
tion. Normal LP, PDL and ABC
2 Mild Gingival hyperplasia, inflammatory cell 
infiltration of the GE and LP. Bacterial 
plaque accumulation. Normal PDL and 
ABC
3 Moderate Erosion/ulceration and hyperplasia of the 
GE and marked bacterial plaque 
accumulation. Moderate inflammatory 
cell infiltration of LP, disruption of PDL, 
migration of the junctional epithelium 
and mild ABC resorption
4 Severe Ulceration/hyperplasia of the GE with 
marked bacterial plaque accumulation. 
Severe inflammatory cell infiltration of LP, 
disruption of PDL, migration of the 
junctional epithelium and marked ABC 
resorption
Note. ABC, alveolar bone crest; GE, gingival epithelium; LP, lamina pro-
pria; PDL, periodontal ligament.
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bone with PD (PD Score ≥1) in rats treated with ZOL 0 (n = 11) or 
ZOL 8–125 (n = 4–12), ZOL-treated rats with BRONJ (n = 10), or ZOL 
0 rats with no PD (n = 12). Osteoclasts were identified in sections 
of paraffin-embedded maxillae using immunohistochemical staining 
of tartrate-resistant acid phosphatase 5b (TRAP), a protein specifi-
cally expressed in active osteoclasts. Slides were deparaffinized and 
endogenous peroxidases were blocked with 3% hydrogen peroxide 
in methanol, and then re-hydrated. Slides were blocked with 2% 
goat serum in Tris-buffered saline with 1% Tween and incubated 
overnight with primary rabbit anti-TRAP at 1:600 dilution (Abcam; 
Cambridge, United Kingdom). Vectastain ABC Rabbit IgG kit (Vector 
Labs; Burlingame, CA, USA) and ImmPACT DAB peroxidase substrate 
kit (Vector Labs) were used to detect signal using manufacturers’ in-
structions. Tissue was counterstained with SelecTech haematoxylin 
560 (Leica; Wetzlar, Germany). Negative control tissues were pro-
cessed the same, but were not incubated with primary antibody. 
TRAP-positive cells were counted on alveolar bone surfaces and 
bone perimeter (B.Pm, mm) was measured using Osteomeasure 
software (Osteometrics Corporation; Decatur, GA, USA) in sections 
from regions that included interdental M1M2 and M2M3 and was 
proximal to the lingual aspect of the molars. The number of TRAP+ 
cells per millimetre of B.Pm was calculated (#/mm).
2.8 | MicroCT
A subset of 40 mandibles underwent MicroCT scanning prior to de-
calcification to characterize the effect of ZOL and BRONJ on calci-
fied tissues of the jaw. Mandibles (n = 10/group) from rats treated 
with 0 or 20–125 µg/kg BW ZOL were grouped according to: (a) 
gross BRONJ; (b) GQG 1–4 with histopathologic BRONJ; (c) GQG 1–4 
without gross BRONJ; and (d) GQG = 0 (ZOL 0). Two-dimensional 
(2D) bone morphology of the mandible was evaluated by 10 µm 
voxel size MicroCT (Bruker Skyscan 1172, Kontich, Belgium) as de-
scribed (Beck et al., 2014; Yarrow, Conover et al., 2014; Yarrow, Ye 
F I G U R E  2   Periodontitis (PD) status 
of control (ZOL 0) rats after weaning 
onto high sucrose-casein (HSC) diet. (a) 
PD prevalence was 0% at 0 weeks and 
peaked at 92% by 30 weeks. (b) Dot 
density plot of PD Score for each rat. 
There was a positive correlation between 
PD Score and time on HSC diet (R = 0.496, 
p = 0.00124). (c) Alveolar bone height 
(ABH), measured as the distance between 
the cementoenamel junction (CEJ) to the 
alveolar bone crest, in mandibles was 
significantly lower after 24 and 30 weeks 
than at 12 and 18 weeks; ABH in maxillae 
was significantly lower after 12, 24 
and 30 weeks compared to baseline; * 
indicates p < 0.05 compared to 12 weeks 
in mandibles, † indicates p < 0.05 
compared to 18 weeks in mandibles, # 
indicates p < 0.05 compared to 0 weeks 
in maxillae. Mean ± SD. (d) Comparison of 
mandibular interdental regions (M1M2) of 
PD Score 0 and PD Score 3; PD Score 3 
is characterized by plaque accumulation 
(‡), epithelial (epi) hyperplasia, junctional 
epithelial apical migration, inflammatory 
infiltrate (black arrow head) in periodontal 
ligament (PDL) and alveolar bone loss
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et al., 2014) and recommended (Bouxsein et al., 2010). Images were 
acquired using the following parameters: 80 kVP/120 µA, 0.5 mm 
aluminium filter, 2k camera resolution, 10 µm voxel size, 0.5° rota-
tion step, and 360° tomographic rotation.
Two analyses were completed. First, 2D images were aligned in 
the mesiodistal plane with all molars simultaneously visible for qual-
itative image analysis. Second, 2D images from the mesial aspect of 
M2 were aligned in the buccolingual plane and the width of the al-
veolar ridge was measured (Figure 9d). Mandibles from ZOL 0 rats 
were compared to rats treated with oncologic ZOL (20–125). To con-
sistently measure the same area in all mandibles, the slice through 
the apical foramen of the mesial root of M2 was selected. Then, the 
vertical length of M2 between the CEJ and apex of the mesial root 
was measured. The buccolingual width of the alveolar ridge was 
then measured perpendicular to the M2 mesial root at 30% (coronal 
width) and 60% (apical width) the total length of the CEJ-apex dis-
tance (ImageJ Software, NIH). After scanning, quadrants underwent 
histopathologic analysis (See Sections 2.6 and 2.7).
2.9 | Peripheral quantitative computed tomography
Peripheral quantitative computed tomography (pQCT) analysis of the 
femur was conducted to verify the anti-resorptive efficacy of ZOL, 
and act as a pharmacodynamic marker of anti-resorptive activity that 
can be compared to BRONJ prevalence. At necropsy, right femurs 
were disarticulated from the acetabulum and separated intact from 
the tibia, wrapped in saline-soaked gauze and stored frozen at −20°C 
until analysis. One-mm-thick cross sections were scanned using a 
Stratec XCT Research M instrument (version 5.40, Norland Medical 
Systems; Fort Atkinson, WI) with manufacturer's software. Sites of 
interest were 5 mm proximal to the distal end of the femur (distal 
metaphysis), and the longitudinal midpoint of the femur (mid-diaphy-
sis). Volumetric bone mineral content (vBMC, mg), volumetric bone 
mineral density (vBMD, mg/cm3) and cortical area (mm2) were deter-
mined for total bone (cancellous and cortical bone at the metaphysis, 
and cortical bone at the mid-diaphysis), as previously described (Ke, 
Qi, Chidsey-Frink, Crawford, & Thompson, 2001).
2.10 | Serum ELISA
Serum concentration of P1NP, a bone formation marker and tartrate-
resistant acid phosphatase 5b (TRAcP 5b), a marker of osteoclast 
number, were measured to characterize the systemic effects of ZOL 
on the skeleton. After cardiac puncture, blood was allowed to clot 
at room temperature and centrifuged, and serum was collected and 
stored at −20°C. Rat/Mouse P1NP EIA and the MouseTRAP kits were 
used, per manufacturer's instructions (Immunodiagnostic Systems; 
Tyne & Wear, UK), in serum collected from rats treated for 24 weeks.
2.11 | Statistical analysis
Chi-square test was used to determine the relationship between 
BW loss and occurrence of BRONJ, between PD type (localized or 
generalized) and oral lesion location (maxilla or mandible), and be-
tween PD type (localized or generalized) and total number of BRONJ 
cases. Multiple logistic regression analysis was used to determine 
whether dose and duration were significant predictors of BRONJ 
prevalence among individual dose levels, and when the doses were 
stratified in three groups: control (ZOL 0), OP (ZOL 8) and oncol-
ogy doses (ZOL 20, 50, 125). Data are expressed as Mean ± SD. For 
ABH, osteocyte lacunae, and ELISA, one-way ANOVA with Holm-
Sidak post hoc analysis was used to assess intergroup differences. 
When assumptions of data normality were not met, a Kruskal–Wallis 
ANOVA on Ranks followed by Dunn's multiple comparison was ap-
plied. Spearman rank correlation was used to determine whether PD 
Score increased with age. Student's t test was used to determine dif-
ferences in the alveolar ridge width measurements between ZOL 0 
and ZOL-treated rats. Two-way ANOVA was used to assess the main 
effects of ZOL dose and duration on pQCT measurements. Two-
way ANOVA was also used to determine the main effects of oral 
health status (healthy, PD, BRONJ) and ZOL dose on TRAP+/B.Pm. 
The means of the ZOL dose groups were collapsed into a single PD 
group for comparison with BRONJ using Student's t test. A power 
calculation was performed using SAS PROC POWER logistic regres-
sion. This experiment has 80% power to determine significant dif-
ferences in BRONJ prevalence between control and 125 µg/kg BW 
ZOL. In all cases, p < 0.05 was considered statistically significant.
3  | RESULTS
3.1 | Periodontitis status (ZOL 0 rats)
All quadrants in baseline rats had GQG 0 with PD Score 0 ± 0. PD 
was prevalent in 60, 56, 80 and 92% of ZOL 0 rats at 12, 18, 24 and 
30 weeks, respectively (Figure 2a). In rats with PD, PD Score ranged 
from 1–4, and there was a significant positive correlation between PD 
Score and duration on HSC diet (R = 0.496, p = 0.00124) (Figure 2b). 
There was significantly greater alveolar bone loss at 24 and 30 weeks 
than at 12 and 18 weeks in mandibles, and at 12, 24 and 30 weeks 
than at baseline in maxillae (Figure 2c). Moderate PD in rice rats (PD 
Score 3) rats showed bacterial plaque, apical migration of junctional 
epithelium, alveolar bone resorption, increased ABH, gingival hyper-
plasia, inflammatory infiltrate, and PDL disruption (Figure 2d).
3.2 | Prevalence of BRONJ‐like lesions
The prevalence of gross BRONJ-like lesions is shown (Figure 3a). 
Neither dose (p = 0.418) nor duration (p = 0.210) were significant 
predictors of gross BRONJ prevalence. When ZOL groups were 
stratified by ZOL 0, OP and oncologic doses (ZOL 20–125), gross 
BRONJ was prevalent in 0%, 2% (1/44) and 18% (23/130) of rats, re-
spectively. Multiple logistic regression showed that dose (p = 0.008), 
but not duration (p = 0.165) was a significant predictor of gross 
BRONJ prevalence when stratified this way.
Histopathologic examination confirmed all 24 cases of gross 
BRONJ and revealed 30 additional cases, for a total of 54 cases of 
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histopathologic BRONJ. The prevalence of histopathologic BRONJ 
is shown (Figure 3b). Histopathologic BRONJ prevalence increased 
steadily with time throughout the experiment (Figure 3c), but his-
topathologic BRONJ prevalence reached a plateau at the ZOL 20 
dose (Figure 3d). Multiple linear regression showed that duration 
(p < 0.001), but not dose (p = 0.076), was a significant predictor 
of overall histopathologic BRONJ prevalence. When ZOL groups 
were stratified by ZOL 0, OP and oncologic doses, histopathologic 
BRONJ was prevalent in 2% (1/42 rats), 18% (8/44 rats) and 35% 
(45/130 rats), respectively. Both ZOL dose (p < 0.001) and duration 
(p < 0.001) were significant predictors of histopathologic BRONJ 
prevalence when stratified this way. One maxilla met all criteria for 
BRONJ in a ZOL 0 rat at age 34 weeks.
3.3 | Features of BRONJ lesions
3.3.1 | Gross and histopathologic
Gross BRONJ-like lesions were found in both maxillae (Figure 4a) 
and mandibles (Figure 4d) and showed exposed bone, ulcerated mu-
cosa, plaque and irregular gingival contours around the margins of 
the molars. Gross oral lesions were distributed evenly between the 
maxillae (46%) and mandibles (54%) (p = 0.1953).
Histopathologic BRONJ-like lesions in both maxillae (Figure 4b,c) 
and mandibles (Figure 4e,f) were characterized by confluent areas of 
empty osteocyte lacunae in bone exposed to the oral cavity, and the 
surface was usually colonized by bacteria. Mucosal and periodontal 
tissues around the margins of the lesions had marked inflammatory 
infiltrate. Haemorrhage, fibrosis, numerous reversal lines in bone 
and necrotic soft tissue were also apparent.
BRONJ-like lesions occurred in different areas of alveolar bone, 
including interdental regions, the M1 interradicular bone, distal to 
M3, or on the hard palate or lingual plate. Necrotic bone was ob-
served underneath intact mucosa in some sections. However, in 
all such cases, exposed necrotic bone was present in sections from 
adjacent levels within the same quadrant (Supporting Information 
Figure S3).
The percentage of empty osteocyte lacunae in BRONJ rats was 
significantly higher (p < 0.05) than in PD control rats in the oncologic 
ZOL dose groups (20–125) (Figure 4g), and similar results were found 
when empty osteocyte lacunae frequency was normalized to bone 
area (Figure 4h).
F I G U R E  3   Prevalence of BRONJ. 
(a) Prevalence of gross BRONJ (high-
resolution photographs). One case was 
found at 24 weeks in the zoledronate 
(ZOL) OP dose; 23 cases were found 
after 12–30 weeks with ZOL oncology 
doses (20–125). (b) Prevalence of 
histopathologic BRONJ. One case was 
found in a ZOL 0 rat at 30 weeks. Eight 
cases were found at 18–30 weeks with 
the ZOL OP dose. Forty-five cases 
were found at 12–30 weeks with ZOL 
oncology doses (20–125). Prevalence of 
histopathologic BRONJ cases within (c) 
each time point and (d) each dose group
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3.3.2 | MicroCT
Periodontitis-affected mandibles exhibited loss of ABH mesial to M1, 
in the M1 furcation, and in the M1M2 interdental region (Figure 5b), 
compared to normal mandibles (Figure 5a). Mandibles affected by 
BRONJ-like lesions exhibited large regions of mottled alveolar bone 
with numerous pores, giving the entire alveolar bone region a hon-
eycomb-like appearance (Figure 5c,d). In severe BRONJ-like lesions, 
F I G U R E  4   Features of necrotic bone in BRONJ-affected maxillae and mandibles of rats injected with zoledronate (ZOL) at gross (a, d) 
and microscopic levels (b, c and e, f). High-resolution photographs of gross BRONJ lesions in (a) maxillae and (d) mandible; note heavy plaque 
accumulation (‡) and ulcerated mucosa with exposed bone (arrow). White lines indicate approximate location of sections shown in b, c and 
e, f. Parasagittal sections through (b, c) the palatal bone of maxillae and (e, f) the mandibular lingual plate with H&E stain; ulcerated mucosa 
with inflammation (black arrowheads) in the lamina propria (LP) and epithelial (epi) hyperplasia; exposed bone surface is colonized by bacteria 
(‡). Border between healthy and necrotic bone is demarcated in yellow. (c, f) Higher magnification of exposed bone tissue shows extensive 
field of empty osteocyte lacunae (yellow arrowheads). (g) The percentage of empty osteocyte lacunae in alveolar bone was higher in BRONJ 
lesions in rats treated with ZOL 20, 50 or 125 compared to BRONJ lesions in ZOL 0 (*p < 0.05) and ZOL 8 (†p < 0.05) rats. (h) The number of 
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profound alveolar bone osteolysis, tooth migration, and spaces with 
apparent missing teeth were noted (Figure 5d). Histological analysis 
from quadrants shown in Figure 5c,d confirmed localized areas of 
exposed, necrotic bone at the M1M2 interdental alveolar bone crest 
and distal to M3.
3.3.3 | Alveolar bone osteoclasts
Compared to ZOL 0 rats with no PD (Figure 6a), ZOL 0 rats with 
PD had more numerous visible multinucleated TRAP+ osteoclasts 
at maxillary alveolar bone surfaces (Figure 6b). TRAP+ cells were 
also visible on alveolar bone surfaces of ZOL-treated rats with PD 
in all dose groups (Figure 6c–f), and numerous TRAP+ cells were vis-
ible on alveolar bone with BRONJ (Figure 6g). There was no TRAP+ 
staining detected in negative control sections (Figure 6h). Two-
way ANOVA revealed no significant effect of ZOL dose on TRAP+ 
cells/B.Pm (p = 0.827), but there was a significant effect of disease 
status (p < 0.001), where alveolar bone with PD and BRONJ had sig-
nificantly more TRAP+ cells/B.Pm, compared to the alveolar bone 
of rats with no PD treated with ZOL 0. There were more TRAP+ 
cells in maxillary alveolar bones in the ZOL 0 PD, ZOL 8 PD and 
ZOL 125 PD groups compared to the alveolar bones of ZOL 0 no 
PD rats (Figure 6i). Since there were no significant effects of ZOL 
dose, the means of each ZOL dose group were collapsed into a single 
PD group and compared to maxillary alveolar bone from rats with 
BRONJ. There were significantly higher numbers of TRAP+ cells/B.
Pm (p = 0.037) in maxillae with BRONJ-like lesions compared to 
maxillae with PD (Figure 6j).
3.3.4 | Skeletal effects of ZOL
Peripheral quantitative computed tomography analysis confirmed 
the anti-resorptive effects of ZOL in both the cancellous and corti-
cal bone compartments. Total metaphyseal vBMD (Figure 7a) and 
vBMC (Figure 7b) were significantly higher in ZOL-treated animals, 
and the response was dependent on both dose (p < 0.001) and dura-
tion (p < 0.001). The highest BMD was observed at 30 weeks in ZOL 
50 and ZOL 125 groups, both of which were significantly different 
from the ZOL 0 and ZOL 8 groups. Both mid-diaphyseal (cortical) 
area (Figure 7c) and mid-diaphyseal vBMC (Figure 7d) were higher 
with dose (p < 0.001) and duration (p < 0.001). There were no sig-
nificant differences among the oncologic doses (ZOL 20–125) at any 
time.
Serum P1NP was dose-dependently lower in ZOL-treated rats 
(p < 0.001) (Figure 8a). All doses of ZOL resulted in significantly lower 
serum P1NP compared to ZOL 0 (p < 0.05). There were no differ-
ences in serum P1NP among the 20, 50 and 125 ZOL groups. Serum 
TRAcP 5b was significantly higher only at the ZOL 50 compared to 
other dose groups (Figure 8b). Serum P1NP was significantly lower 
in rats treated with ZOL 20–125 with BRONJ-like lesions, compared 
to rats treated with either ZOL 0 or ZOL 20–125 without BRONJ 
(Figure 8c). Conversely, serum TRAcP 5b was significantly higher 
in rice rats treated with ZOL 20–125 with BRONJ-like lesions com-
pared to rice rats treated with either ZOL 0 or ZOL 20–125 without 
BRONJ (Figure 8d).
ZOL-treated rats had significantly increased width of mandibular 
alveolar processes (p < 0.05) (Figure 9a). While buccal plate width 
of rats treated with ZOL 20–125 was the same as ZOL 0 control 
(Figure 9b), the lingual plate was significantly wider at the apical por-
tion of the alveolar process (p < 0.05) (Figure 9c).
4  | DISCUSSION
This study demonstrates that longer duration of oncologic doses of 
ZOL is associated with a higher prevalence of BRONJ in rice rats that 
are simultaneously developing generalized PD. BRONJ prevalence 
appeared to plateau at an oncologic ZOL dose (ZOL 20) that was 
F I G U R E  5   Representative 2D MicroCT 
slices of mandibles from rats treated 
with oncologic doses of zoledronate 
(ZOL) (20–125). (a) Normal mandible. 
(b) Mandibles with PD-only showed 
loss of alveolar bone height mesial 
to M1, in the M1 furcation and in the 
M1M2 interdental region (red lines). (c) 
Mandibles with BRONJ showed mottled, 
honeycomb-like appearance in the entire 
alveolar process (green arrowheads), 
but not the cortical bone of the inferior 
border of the mandible. (d) In more severe 
BRONJ, profound bone destruction, 
tooth migration and tooth loss were 
observed along with the honeycomb-like 
appearance of the alveolar process
(a) (b)
(c) (d)
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only 2.5-fold higher than the OP dose. A similar plateau at the ZOL 
20 dose was observed for the known anti-resorptive effect of ZOL, 
as indicated by a plateau in bone mass. Finally, ZOL treatment and 
BRONJ-like lesions produced tissue-level effects on the jaws that 
were distinctive from both healthy rats, and rats with generalized 
PD that did not receive ZOL. The pattern of prevalence and the tis-
sue-level effects on the jaws support the overall hypothesis that 
systemic ZOL administration induces BRONJ-like lesions in distinct 
patterns depending on the different types of local oral inflammatory 
conditions.
F I G U R E  6   Osteoclasts in the maxillary alveolar bone of rice rats treated with zoledronate (ZOL). Representative images of TRAP+ 
immunolabelled osteoclasts (red arrow heads) on the maxillary alveolar bone surfaces of (a) rats with no PD treated with ZOL 0, and rats 
with PD treated with either (b) ZOL 0, (c) ZOL 8, (d) ZOL 20, (e) ZOL 50 or (f) ZOL 125. (g) Numerous TRAP+ osteoclasts in alveolar bone 
affected by BRONJ. Plaque (‡) is visible in PD-affected maxillae and is directly attached to necrotic bone (demarcated in yellow) in BRONJ. 
(h) Absence of TRAP+ staining in negative control. (i) Number of TRAP+ osteoclasts per mm of bone perimeter (B.Pm) in alveolar bone of 
rats with no PD treated with ZOL 0, and rats with PD treated with various doses of ZOL (0–125); * indicates p < 0.05 compared to ZOL 0 no 
PD control. (j) TRAP+ cells per mm B.Pm in alveolar bone affected by PD or BRONJ. * indicates p < 0.05 compared to PD. Mean ± SD
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This study supports the role of local oral inflammation as a key 
component in the development of BRONJ that is not directly related 
to dental surgery. The current study, along with studies in other 
rodent models, has shown that BRONJ-like lesions can arise from 
several types of oral inflammation processes or wounds, which is 
consistent with human MRONJ. BRONJ-like lesions have been ob-
served when ZOL treatment is combined with mechanically exposed 
dental pulp (Kang et al., 2013; Wayama et al., 2015), experimental 
F I G U R E  7   Peripheral quantitative 
computed tomography of the femoral 
distal metaphysis and mid-diaphysis 
after treatment with zoledronate (ZOL) 
0–125 for up to 30 weeks, starting at 
age 4 weeks. (a) Total distal metaphyseal 
volumetric bone mineral density (vBMD; 
mg/cm3); (b) total volumetric distal 
metaphyseal bone mineral content 
(vBMC; mg/mm); (c) total cortical bone 
area (mm2); and (d) cortical vBMC (mg/
mm). The main effects of dose (p < 0.001) 
and time (p < 0.001) were significant for 
all measurements, and there were some 
significant differences among doses 
within each time point. However, there 
were no significant differences among 
the ZOL oncology doses at any time. 
*indicates p < 0.05 compared to 0 ZOL; ‡ 
indicates p < 0.05 compared to 0 ZOL and 
8 ZOL. Mean ± SD
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PD via dental ligature (Li et al., 2016) and in association with local-
ized intraoral lesions where impacted food and hair produce peri-
odontal inflammation (Messer et al., 2018; de Molon et al., 2014). 
The requirement of local oral factors is also supported in the current 
study by a subpopulation of rice rats (32%) given oncologic doses of 
ZOL that never developed BRONJ despite receiving cumulative ZOL 
doses up to 1,000 µg/kg over 30 weeks. These rats had GQG of 0 
(92%) or 1 (8%), and exhibited no BW loss at necropsy, suggesting 
healthy oral cavities. Similarly, Sprague Dawley rats treated up to 
2 years with alendronate at up to 10 times the OP dose and ZOL at 
up to seven times the oncology dose show no BRONJ-like lesions 
(Merck, 2018; Novartis, 2018), possibly because of the known resis-
tance of rodents from the genus Rattus to develop PD (Graves, Kang, 
Andriankaja, Wada, & Rossa, 2012; Oz & Puleo, 2011; Struillou, 
Boutigny, Soueidan, & Layrolle, 2010; Weinberg & Bral, 1999).
While inflammation or infection from oral diseases, or direct 
compromise of the gingival barrier via a wound, appears to be crucial 
for developing BRONJ, evidence from rice rat studies suggests that 
the type of oral inflammation may produce BRONJ in distinctive 
patterns, and with distinctive features when bone resorption is sup-
pressed by ZOL. In the FILP model, BRONJ-like lesions developed 
primarily in maxillae (74%) compared to mandibles (26%) (p < 0.0001), 
and there was a significant increase in prevalence dependent on 
dose, but not duration of ZOL treatment (Messer et al., 2018). In the 
current study, rice rats fed the HSC diet developed generalized PD 
but not FILP. In this generalized PD model, BRONJ lesions were dis-
tributed evenly between maxillae and mandibles, and were associ-
ated with ZOL duration, but not dose. The FILP model also produced 
a significantly higher total prevalence of histopathologic BRONJ 
compared to the generalized PD model (p < 0.0001), at 47% (82/174) 
vs 31% (53/171), respectively (Messer et al., 2018). The distinctive 
relationships between ZOL and BRONJ prevalence may reflect dif-
ferences in the initiation and progression of the two types of PD. The 
highest BRONJ prevalence in the generalized PD model occurred at 
F I G U R E  8   Serum bone turnover marker concentration in rice rats. (a) P1NP and (b) TRAcP 5b after treatment with ZOL 0–125 for 
24 weeks. *p < 0.05 compared to ZOL 0; †p < 0.05 compared to ZOL 8. (c) P1NP and (d) TRAcP 5b in rats treated with ZOL 0 or oncologic 
ZOL doses (20–125) for 24 weeks and grouped by BRONJ status; *indicates p < 0.05 compared to non-BRONJ ZOL 0; **indicates p < 0.05 
compared to non-BRONJ ZOL 0 and non-BRONJ ZOL 20–125. Non-BRONJ ZOL 0, n = 9; non-BRONJ ZOL 20–125, n = 18; BRONJ ZOL 
20–125, n = 8. Mean ± SD
     |  1129MESSER Et al.
30 weeks, while the highest prevalence of BRONJ in the FILP model 
occurred at 18 weeks and plateaued at later time points (Messer et 
al., 2018). This pattern is congruent with the time points in which 
the PD lesions become moderate to severe in each model, as FILP 
occurs in up to 75% of rice rats by age 16 weeks (Messer et al., 2018), 
while destruction of tissues in the generalized PD model was more 
prevalent and more severe in this study after 24–30 weeks. These 
data suggest that the FILP model may be more severe, and produces 
BRONJ-like lesions more rapidly compared to generalized PD. The 
direct trauma to the soft tissues from the impacted materials of the 
FILP lesion may directly introduce microorganisms to periodontal 
tissues through the wound, which is in contrast to generalized PD, 
which is characterized by accumulation of plaque on tooth surfaces, 
and inflammation in the gingival and periodontal tissue. The differ-
ent effects of the local oral factors on the time-to-onset of BRONJ in 
the two rice rat PD models may partly explain findings in humans, in 
which the time-to-onset of BRONJ after exposure to pARs is widely 
variable, ranging from 0.1 to 19.9 years (Fung et al., 2017).
The histopathological examination of BRONJ-like lesions at the 
tissue level was consistent with previous studies in rice rats, where 
exposed necrotic bone with attached bacterial colonies was ob-
served (Aguirre, Akhter, Kimmel, Pingel, Xia et al., 2012). In the cur-
rent study, osteonecrosis was not found under intact mucosa in any 
of the 198 examined quadrants. Additionally, four lesions showed 
bone that was exposed, but vital. Taken together, these novel find-
ings suggest that bone in the periodontal lesion of pAR-treated 
subjects may become exposed before becoming necrotic. “Stage 
0” MRONJ in humans, in which nonspecific clinical findings, radio-
graphic changes and symptoms are reported without clinical evi-
dence of necrotic bone, could have exposed, necrotic bone in deep 
periodontal pockets, or in periapical regions of severely carious or 
endodontically treated teeth with chronic infection. Patients taking 
F I G U R E  9   Width of alveolar process of mandibles in rice rats treated with ZOL 0 or oncologic ZOL doses (20–125). (a) total alveolar 
process width, (b) buccal plate width and (c) lingual plate width; (d) diagram of apical and coronal sites of measurement. *indicates p < 0.05 
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pARs with clinical findings of moderate/advanced PD or periapical 
pathology, such as bleeding on probing or intermittent tooth sensi-
tivity, may actually have exposed, necrotic bone in periodontal pock-
ets or in the periapical region that is only histologically detectable.
One maxilla met all criteria for a BRONJ-like lesion in a ZOL 0 rat 
at age 34 weeks, indicating that dead alveolar bone in rice rats with 
severe PD that were not treated with a pAR, can occasionally accu-
mulate in sufficient quantity to be diagnosed as BRONJ. Bone necro-
sis is not generally observed in clinical examination of humans with 
severe PD who do not take pARs. This may be due to lack of routine 
tissue biopsy of severe PD lesions in humans, or because necrotic 
bone may be promptly removed by normal osteoclastic activity in 
the absence of pARs. Indeed, delayed removal of necrotic bone in 
humans taking pARs has been observed clinically in the treatment of 
femoral head osteonecrosis (Agarwala & Shah, 2011; Hong, Luo, Lin, 
Zhong, & Shi, 2014; Lai et al., 2005; Luo, Lin, Zhong, Yan, & Wang, 
2014), suggesting that pARs may also cause persistence of necrotic 
bone induced by severe PD in the oral cavity, which could eventually 
result in clinically detectable MRONJ. Alternatively, oral ulceration 
with bone sequestration (Almazrooa & Woo, 2009; Farah & Savage, 
2003; Khan et al., 2015; Palla, Burian, Klecker, Fliefel, & Otto, 2016; 
Peters, Lovas, & Wysocki, 1993; Sonnier & Horning, 1997) occurs 
in humans not taking pARs and may have some relevance to this 
finding.
MicroCT images of mandibles affected with BRONJ-like lesions 
revealed mottling of alveolar bone distant from the necrotic bone 
tissue region identified histologically. These pores may be the re-
sult of osteoclast activity far from localized sites where necrotic 
bone has accumulated. This finding suggests that the presence 
of exposed necrotic bone tissue may activate bone resorption 
throughout the entire alveolar process of the afflicted quadrant, 
bearing similarity to a regional acceleratory phenomenon (RAP) 
(Duncan, Frame, Frost, & Arnstein, 1969; Frost, ; Mueller, Schilling, 
Minne, & Ziegler, 1991; Verna, 2016). Indeed, the number of TRAP+ 
osteoclasts per mm bone perimeter was significantly higher in max-
illary alveolar bone of BRONJ-affected rats, compared to maxillary 
alveolar bone of rats affected by PD, suggesting that exposed 
necrotic bone with a more extensive area of soft tissue damage 
and inflammation promote a greater recruitment and activation of 
osteoclasts.
MicroCT analysis also revealed that ZOL monotherapy can in-
crease the width of the alveolar process in rice rats. This provides 
further evidence that in rats at risk for BRONJ, the entire alveolar 
process, not just the interdental and interradicular alveolar bone, is 
altered. This finding may also have important implications for pa-
tients with complete or partial removable dentures. Expanding bone 
width under the dentures may increase the likelihood of mucosal 
tissue compression, and initiate pressure sores and mucosal epithe-
lium necrosis that can lead to bone exposure and MRONJ. MRONJ 
has been documented in patients wearing removable complete or 
partial dentures (Bamias et al., 2005; Kyrgidis et al., 2008; Levin, 
Laviv, & Schwartz-Arad, 2007; Niibe, Ouchi, Iwasaki, Nakagawa, 
& Horie, 2015; Tsuji, Watanabe, Nakayama, Goto, & Kurita, 2017; 
Zarychanski, Elphee, Walton, & Johnston, 2006). While observation 
of edentulous alveolar ridges in pAR patients with cone beam CT 
may be currently limited by the conventional 0.125 mm voxel size, 
these findings suggest that paying close attention to the condition 
of the mucosa underlying removable dentures in pAR patients may 
reduce the incidence of MRONJ not related to dental surgery.
Oncologic doses of ZOL resulted in a roughly twofold higher 
prevalence of BRONJ compared to the OP dose (35% vs 18%, re-
spectively), supporting the idea that oncologic doses of ZOL result 
in higher BRONJ prevalence. However, the prevalence of BRONJ 
was 38% (20/53) in rats treated with ZOL 20, which is only 2.5-fold 
higher than the OP dose, and at the low end of the oncologic range, 
while the prevalence of BRONJ with ZOL 125, roughly 16-fold higher 
than the OP dose, was only 26% (14/53). These data most likely in-
dicate a prevalence plateau beginning at ZOL 20. A similar plateau 
was observed in bone mass and systemic measurement of bone for-
mation marker P1NP. Specifically, ZOL increased femoral BMD and 
BMC, which plateaued around the ZOL 20 dose, and serum P1NP 
was reduced to similar levels by ZOL after 24 weeks of treatment. 
Serum TRAcP 5b was not significantly altered by ZOL except at the 
ZOL 50 dose, which was higher than control (ZOL 0) and other ZOL 
doses. Together, these findings suggest that BRONJ prevalence 
may be associated specifically with the well-characterized anti-re-
sorptive effect of ZOL, and that the primary systemic effect of ZOL 
on osteoclasts in this model is likely attributed to decreased os-
teoclast activity, rather than decreased osteoclast numbers. When 
levels of serum turnover markers were stratified by BRONJ status, 
ZOL-treated rats with BRONJ had significantly lower P1NP and sig-
nificantly higher TRAcP 5b compared to ZOL-treated rats without 
BRONJ. These findings indicate that BRONJ was associated with sig-
nificantly suppressed systemic bone formation and high numbers of 
osteoclasts. Together, these findings have important implications in 
clinical studies that attempt to reduce the cumulative dose of pARs 
in oncology patients to reduce the incidence of MRONJ (Amadori et 
al., 2013; Corso et al., 2007; Himelstein et al., 2017; Hortobagyi et 
al., 2017). If both prevalence of MRONJ and prevention of skeletal-
related events are associated primarily with anti-resorptive activity, 
then lowering the pAR dose enough to reduce MRONJ prevalence 
may coincidently compromise the efficacy of pARs in reducing skel-
etal-related events.
The local effects of ZOL, PD and BRONJ on the number of os-
teoclasts present in maxillary alveolar bones of the experimental rice 
rats were also histopathologically evaluated. In this study, increased 
numbers of TRAP+ osteoclasts and increased loss of ABH were 
observed in ZOL 0 rats with PD, compared to ZOL 0 healthy rats, 
which represent well-established pathologic features of PD. The 
addition of ZOL treatment to rats with PD did not result in any sig-
nificant alteration in the number of TRAP+ cells at any dose. These 
findings suggest that: 1) the inflammation associated with PD plays 
an important role in the increased number of osteoclasts observed 
in maxillary alveolar bones of rice rats, but 2) ZOL does not have 
any significant influence in affecting the number of osteoclasts in 
the jaws, even at very high oncologic doses. This is in contrast with 
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the findings published by Weinstein et al. of human transilial bi-
opsy samples from osteoporosis patients treated with alendronate, 
which showed higher numbers of osteoclasts in cancellous bone of 
patients treated with an osteoporosis dose of 10 mg/day compared 
to placebo, but no effects in osteoclast number at 1 or 5 mg/day 
(Weinstein, Roberson, & Manolagas, 2009). These discrepant find-
ings at the bone tissue level between osteoporosis patients and rice 
rats may be due to variation in the dose (osteoporosis vs oncologic) 
and type of bisphosphonate (ZOL vs alendronate), and in particular, 
differences in the specific bone type and microenvironments asso-
ciated with PD and osteoporosis. Maxillary alveolar bone is anatom-
ically and functionally different from the trabecular bone from the 
pelvis. In addition, jawbones of PD-affected rats are in close prox-
imity to pathogenic microbes of the oral cavity. The inflammatory 
microenvironment of PD therefore bears limited similarity to the 
non-inflamed microenvironment in trabecular bone of the iliac crest. 
Taken together, these findings support the idea that the unique an-
atomical and physiological features of alveolar bone play an import-
ant role in the specificity of osteonecrosis to the jaws.
The design of this study limits the interpretation of our findings 
in a few important ways. First, ZOL injections began in normal, peri-
odontally healthy rice rats. Two injections occurred at ages 4 and 
8 weeks, when the skeleton is considered juvenile. Since MRONJ 
is an adverse event that occurs in humans first exposed to pARs 
in adulthood, future rice rat studies should begin administration 
of MRONJ-inducing medications after the skeleton has matured 
(after age 12 weeks) to improve the parallel with the human con-
dition. Second, human MRONJ also occurs in the setting of cancer 
or osteoporosis where patients, unlike rice rats, not only have a pri-
mary disease, but also receive other types of medications. These 
underlying health issues, or drug treatments, particularly in cancer 
patients, may elevate the risk of MRONJ. For example, corticoste-
roids, which negatively influence healing (Rubin & Palestine, 1989; 
Zitelli, 1987), are frequently used in treatment protocols for patients 
with cancer or autoimmune/inflammatory diseases that cause sec-
ondary osteoporosis (e.g., rheumatoid arthritis), and may suppress 
healing of oral wounds. This could account for the observation that 
humans exposed to oncology doses of ZOL have a roughly 200-fold 
higher prevalence of MRONJ than osteoporosis patients (Coleman, 
Marshall et al., 2011; Coleman, Woodward et al., 2011; Grbic et al., 
2010; Rathbone et al., 2013; Ruggiero et al., 2014), which is much 
higher compared to rice rat data, where oncology doses produced 
only 2- to 10-fold higher BRONJ prevalence compared to the OP 
dose after 30 weeks. Third, this study is limited by our inability to 
fully examine PD and BRONJ in live animals. Thirty-six per cent of 
BRONJ cases were found in rice rats with no gross oral cavity lesions 
(GQG < 1), but were symptomatic in the sense that the rats experi-
enced loss of body weight. Diagnostic criteria available in the clin-
ical setting (e.g., periodontal probing, patient-reported pain, dental 
radiography, cone beam CT) cannot be achieved in a rodent study, 
so the exact progression of PD and BRONJ, or any spontaneous 
healing, could not be assessed. Finally, observations of BRONJ in 
rice rats at necropsy did not allow assessment of the duration of 
bone exposure. Longitudinal observations and oral examinations in 
live rice rats in future studies may address some of these limitations.
The reduction in morbidities and mortality, along with the low risk 
of MRONJ, strongly favours the continued use of pARs in humans. 
Therefore, completely describing the aetiology and pathophysiology 
of MRONJ is more important than ever to patient safety, and could 
provide evidence that allows development of prevention and treat-
ment strategies for both dental surgery-related and non-surgery-re-
lated MRONJ. Additionally, recent case reports describe patients with 
MRONJ who were not exposed to anti-resorptive or anti-angiogenic 
medications (Aghaloo & Tetradis, 2017), suggesting that MRONJ re-
mains an emerging disease that may be associated with yet other med-
ical conditions or drugs.
5  | CONCLUSION
This study demonstrates a duration-dependent increase in the prev-
alence of BRONJ with oncologic ZOL in rice rats with progressive 
generalized PD. BRONJ prevalence plateaued at a dose only 2.5-fold 
higher than prevalence with the osteoporosis dose and was con-
sistent with a similar plateau in the anti-resorptive effects of ZOL. 
BRONJ and ZOL also produced unique alterations at the tissue level 
compared to PD and healthy rats treated with ZOL. The findings 
demonstrate that local oral risk factors play a key role in establishing 
an environment in which systemic medications can induce BRONJ, 
but that different local factors may interact with pARs in distinctive 
ways.
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